These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37994801)

  • 41. Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.
    Scott JS; Stead D; Barlaam B; Breed J; Carbajo RJ; Chiarparin E; Cureton N; Davey PRJ; Fisher DI; Gangl ET; Grebe T; Greenwood RD; Hande S; Hatoum-Mokdad H; Hughes SJ; Hunt TA; Johnson T; Kavanagh SL; Klinowska TCM; Larner CJB; Lawson M; Lister AS; Longmire D; Marden S; McGuire TM; McMillan C; McMurray L; Morrow CJ; Nissink JWM; Moss TA; O'Donovan DH; Polanski R; Stokes S; Thakur K; Trueman D; Truman C; Tucker MJ; Wang H; Whalley N; Wu D; Wu Y; Yang B; Yang W
    J Med Chem; 2023 Feb; 66(4):2918-2945. PubMed ID: 36727211
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of a multi-target compound for estrogen receptor-positive (ER
    Almeida CF; Teixeira N; Oliveira A; Augusto TV; Correia-da-Silva G; Ramos MJ; Fernandes PA; Amaral C
    Biochimie; 2021 Feb; 181():65-76. PubMed ID: 33278557
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present).
    Scott JS; Barlaam B
    Expert Opin Ther Pat; 2022 Feb; 32(2):131-151. PubMed ID: 34763600
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.
    Rej RK; Thomas JE; Acharyya RK; Rae JM; Wang S
    J Med Chem; 2023 Jul; 66(13):8339-8381. PubMed ID: 37377342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer.
    Chen YC; Yu J; Metcalfe C; De Bruyn T; Gelzleichter T; Malhi V; Perez-Moreno PD; Wang X
    Expert Opin Investig Drugs; 2022 Jun; 31(6):515-529. PubMed ID: 34694932
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
    He M; Ning W; Hu Z; Huang J; Dong C; Zhou HB
    Eur J Med Chem; 2020 Jun; 195():112281. PubMed ID: 32283297
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Dual Estrogen Receptor α Inhibitory Effects of the Tissue-Selective Estrogen Complex for Endometrial and Breast Safety.
    Han SJ; Begum K; Foulds CE; Hamilton RA; Bailey S; Malovannaya A; Chan D; Qin J; O'Malley BW
    Mol Pharmacol; 2016 Jan; 89(1):14-26. PubMed ID: 26487511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Deoxybenzoins are novel potent selective estrogen receptor modulators.
    Papoutsi Z; Kassi E; Fokialakis N; Mitakou S; Lambrinidis G; Mikros E; Moutsatsou P
    Steroids; 2007 Sep; 72(9-10):693-704. PubMed ID: 17659312
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy.
    Pan M; Solozobova V; Kuznik NC; Jung N; Gräßle S; Gourain V; Heneka YM; Cramer von Clausbruch CA; Fuhr O; Munuganti RSN; Maddalo D; Blattner C; Neeb A; Sharp A; Cato L; Weiss C; Jeselsohn RM; Orian-Rousseau V; Bräse S; Cato ACB
    Cancer Res Commun; 2023 Jul; 3(7):1378-1396. PubMed ID: 37520743
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Aryl Hydrocarbon Receptor Ligand 6-Formylindolo(3,2-b)carbazole Promotes Estrogen Receptor Alpha and c-Fos Protein Degradation and Inhibits MCF-7 Cell Proliferation and Migration.
    Cano-Sánchez J; Murillo-González FE; de Jesús-Aguilar J; Cabañas-Cortés MA; Tirado-Garibay AC; Elizondo G
    Pharmacology; 2023; 108(2):157-165. PubMed ID: 36657432
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer.
    Xin L; Wang C; Cheng Y; Wang H; Guo X; Deng X; Deng X; Xie B; Hu H; Min C; Dong C; Zhou HB
    J Med Chem; 2024 Jun; 67(11):8913-8931. PubMed ID: 38809993
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rational design, synthesis, antiproliferative activity against MCF-7, MDA-MB-231 cells, estrogen receptors binding affinity, and computational study of indenopyrimidine-2,5-dione analogs for the treatment of breast cancer.
    Ejaz I; Javed MA; Jan MS; Ikram M; Sadiq A; Ahmad S; Rashid U
    Bioorg Med Chem Lett; 2022 May; 64():128668. PubMed ID: 35276362
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel 11β-substituted estradiol conjugates: Transition from ERα agonizts to effective PROTAC degraders.
    Luo G; Li X; Lin X; Lu X; Li Z; Xiang H
    J Steroid Biochem Mol Biol; 2022 Oct; 223():106154. PubMed ID: 35870675
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development.
    Thaler S; Schmidt M; Schad A; Sleeman JP
    Oncogene; 2012 Nov; 31(47):4912-22. PubMed ID: 22266866
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.
    Wang Y; Tang SC
    Cancer Metastasis Rev; 2022 Dec; 41(4):975-990. PubMed ID: 36229710
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of heterodimeric estrogen receptor alpha antagonists to target simultaneously the ligand and coactivator binding site.
    Hörmann N; Kalchschmid C; Grabher P; Grassmayr I; Kapitza P; Kaserer T; Gust R
    Arch Pharm (Weinheim); 2023 Jul; 356(7):e2200638. PubMed ID: 37173820
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Elucidating Binding Sites and Affinities of ERα Agonists and Antagonists to Human Alpha-Fetoprotein by In Silico Modeling and Point Mutagenesis.
    Moldogazieva NT; Ostroverkhova DS; Kuzmich NN; Kadochnikov VV; Terentiev AA; Porozov YB
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019136
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer.
    Deng X; Deng X; Ning W; Xin L; Li Q; Hu Z; Xie B; Liang K; Min C; Dong C; Huang J; Zhou HB
    J Med Chem; 2023 Aug; 66(16):11094-11117. PubMed ID: 37584263
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Estrogen-mediated inactivation of FOXO3a by the G protein-coupled estrogen receptor GPER.
    Zekas E; Prossnitz ER
    BMC Cancer; 2015 Oct; 15():702. PubMed ID: 26470790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tamoxifen and Fulvestrant Hybrids Showed Potency as Selective Estrogen Receptor Down-Regulators.
    Shoda T; Kato M; Fujisato T; Demizu Y; Inoue H; Naito M; Kurihara M
    Med Chem; 2017; 13(3):206-213. PubMed ID: 27494098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.